-
CEO Stephane Bancel said Moderna gave the government a discount with its initial prices. Now, the company must assume more costs and risk, he said.
-
Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.
-
The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in survival before the cancer returned in patients with advanced melanoma.
-
Moderna CEO Stephane Bancel said in a prepared statement that the vaccine developer pioneered that technology and invested billions of dollars in creating it.
-
Advisers to the CDC voted unanimously to recommend Moderna's shots as an option for school-age kids and adolescents. This age group has been able to get shots shots made by Pfizer since last year.
-
The consensus has been that Pfizer and Moderna are most protective. But a study looking at 5 vaccines — including Russia's Sputnik V and two Chinese types — offers an unexpected finding.
-
The vaccine maker’s COVID-19 shots, which are now available in more than 70 countries, totaled $17.7 billion in sales last year, their first full year on the market.
-
Moderna said its current FDA-authorized 50-microgram booster shot increased antibody levels against omicron 37-fold compared to pre-booster levels.
-
The Moderna vaccine's ability to shield against infection drops sharply when tested on the omicron variant. But getting a booster pumps the protection back up again, new research suggests.
-
The FDA on Friday granted emergency use authorization for the Pfizer-BioNTech and Moderna booster shots. The boosters have already been available for people 65 and older and to high-risk adults.